Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

83.31EUR
4:53am EDT
Change (% chg)

€-0.16 (-0.19%)
Prev Close
€83.47
Open
€83.90
Day's High
€84.00
Day's Low
€83.23
Volume
315,198
Avg. Vol
2,518,210
52-wk High
€84.00
52-wk Low
€62.50

SASY.PA

Chart for SASY.PA

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including... (more)

Overall

Beta: 0.89
Market Cap(Mil.): €107,845.10
Shares Outstanding(Mil.): 1,292.02
Dividend: 2.96
Yield (%): 3.55

Financials

  SASY.PA Industry Sector
P/E (TTM): 24.64 29.17 29.94
EPS (TTM): 3.39 -- --
ROI: 5.02 13.48 13.01
ROE: 7.60 14.39 14.16

BRIEF-Vivus reacquires Stendra(R)(AVANAFIL)commercial rights from Sanofi

* Reacquires Stendra(R) (Avanafil) commercial rights from Sanofi

Mar 27 2017

Doctors, patients urge court to reject ban on cholesterol drug sales

A group of doctors and patients are urging a federal appeals court to overturn a lower court order banning sales of Sanofi SA and Regeneron Pharmaceuticals Inc's cholesterol drug Praluent after Amgen Inc won a patent lawsuit against them.

Mar 23 2017

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

LONDON Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival.

Mar 23 2017

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

LONDON Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival.

Mar 23 2017

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

LONDON, March 23 Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival.

Mar 23 2017

BRIEF-Sanofi genzyme extends its multiple myeloma journey partners program

* Sanofi genzyme extends its multiple myeloma journey partners program to cities nationwide to help improve patient outcomes through peer-to-peer education Source text for Eikon: Further company coverage:

Mar 22 2017

Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims

BOSTON Sanofi SA and Regeneron Pharmaceuticals Inc have filed a lawsuit seeking a court order declaring that their eczema drug Dupixent, awaiting a U.S. approval decision, does not infringe an Amgen Inc patent for a failed asthma treatment.

Mar 21 2017

Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims

BOSTON Sanofi SA and Regeneron Pharmaceuticals Inc have filed a lawsuit seeking a court order declaring that their eczema drug Dupixent, awaiting a U.S. approval decision, does not infringe an Amgen Inc patent for a failed asthma treatment.

Mar 21 2017

UPDATE 1-Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims

BOSTON, March 21 Sanofi SA and Regeneron Pharmaceuticals Inc have filed a lawsuit seeking a court order declaring that their eczema drug Dupixent, awaiting a U.S. approval decision, does not infringe an Amgen Inc patent for a failed asthma treatment.

Mar 21 2017

Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims

BOSTON, March 21 Sanofi SA and Regeneron Pharmaceuticals Inc filed a lawsuit seeking a court order declaring that their eczema drug Dupixent, awaiting a U.S. approval decision, does not infringe an Amgen Inc patent for a failed asthma treatment.

Mar 21 2017

More From Around the Web

Earnings vs. Estimates